한국어
Quantus

DRTECH

214680 · KOSDAQ
₩5,040+425.00%
2026-09-10 close

DRTECH last closed at ₩5,040 (+425.00%) on 2026-09-10. Signals today: Golden cross. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
Market Leader RS 98 · top 2%골든크로스 · 0d 전

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
267 picks
Next-day win rate
53.4%
Avg next-day
+0.05%
vs market
-0.86%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

PER — · PBR 5.13 — own-history percentile 16/100 · 6/100

Open self-history band
PER16/100
PBR6/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.35
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
2.35
Beneish M-Score
-2.19

No statistical flag

Sloan accrual
-1.82%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

차입 증가 → 이자부담 → 수익성 악화

Critical

부채가 +34.1% 늘며 이자보상배율이 0.1x에서 -2.8x로 하락했다. ROE도 0.1%에서 -16.6%로 낮아져 차입 부담이 수익성을 누르고 있다.

Evidence

부채 YoY +34.1%이자보상배율 0.1x→-2.8xROE 0.1%→-16.6%

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -16%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Cash conversion cycleWarning

현금전환주기(CCC) 4기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (0.1% → -12.4%, -12.5%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 40% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-12.4%
Interest coverage
-2.8x
Return on equity (ROE)
-26.5%

Operating margin −5pp

Operating loss
Interest coverageBase -2.8x adverse case -3.9x
Return on equity (ROE)Base -26.5% adverse case -29.4%

Revenue −15%

Interest coverage risk
Interest coverageBase -2.8x adverse case -2.3x
Return on equity (ROE)Base -26.5% adverse case -20.2%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -2.8x adverse case -1.9x
Return on equity (ROE)Base -26.5% adverse case -25.6%

Interest coverage limit

Already below the limit by 16.9pp

Interest coverage limit at an operating margin of 4.5%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-20

Suppliers disclosed by the company in its 2026-03-20 annual report.

Suppliers without disclosed amount

디알텍씨텍메디칼TFTDetectorSystemCapaAxBxCDRTECHNorthAmericaIncEurope+21 more

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 케이메디컬밸류업11.08%2026-06-30 · 증감 +11.08%p
  • 아트만자산운용10.98%2026-07-13 · 증감 -0.08%p
  • 오스템임플란트9.88%2026-01-05 · 증감 +3.75%p
  • 윤정기5.84%2026-04-30 · 증감 -0.92%p

Connections

AI-extracted related companies · for reference

Customers
GE HealthCareSiemens HealthineersPhilipsCanon Medical SystemsShenzhen MindraySamsung MedisonVarian Medical Systems
Competitors
Varex ImagingTeledyne DALSAKonica MinoltaFujifilmCanonToshiba
Same theme
Siemens
🔗 See in the full market map →

Recent filings

DRTECH's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About DRTECH
What technical signals does DRTECH (214680) have?
DRTECH current technical signals: golden cross (5_20, 0d ago).
Is DRTECH a cup-and-handle pattern?
No. DRTECH has no valid cup-and-handle signal right now.
What are DRTECH's financials and valuation?
DRTECH's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy